Serial #79435549
LIVE

Serial Number

79435549

Owner

Maxion Therapeutics Limited

Attorney

Ben Natter

Filing Date

Sep 24, 2025

Add to watchlist:

No watchlists yet
View on USPTO

Serial #79435549 Trademark

Serial Number: 79435549 • Registration: 8217704

Serial #79435549 is a trademark filed by Maxion Therapeutics Limited on September 24, 2025. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently registered and active.

Owner Contact Info

Maxion Therapeutics Limited (4 trademarks)

C/O Mishcon de Reya,

Entity Type: 99

Trademark Details

Filing Date

September 24, 2025

Registration Date

April 21, 2026

Published for Opposition

March 3, 2026

Goods & Services

Pharmaceuticals and pharmaceutical preparations for the treatment of diseases and conditions associated with dysregulation of ion channel or G-protein-coupled receptor activity, including preparations for the prevention and treatment of pain, autoimmunity, cardiovascular disease and cancer; drugs, namely, pharmaceutical preparations for the treatment of diseases and conditions associated with dysregulation of ion channel or G-protein-coupled receptor activity, including those for use in the prevention and treatment of pain, autoimmunity, cardiovascular disease and cancer; engineered antibodies for medical use; pharmaceuticals, drugs and pharmaceutical preparations incorporating engineered antibodies, ion channel modulating or G-protein-coupled receptor modulating engineered antibodies or engineered antibodies derived from mini-protein toxins; vaccines

Chemicals for use in industry and science; biochemicals, namely, polypeptides and engineered antibodies for scientific, laboratory or research purposes; polypeptides and engineered antibodies for use in the manufacture of pharmaceuticals and drugs; ion channel modulating or G-protein-coupled receptor modulating engineered antibodies for scientific, laboratory or research purposes; ion channel modulating or G-protein-coupled receptor modulating engineered antibodies for use in the manufacture of pharmaceuticals and drugs; engineered antibodies derived from mini-protein toxins for scientific, laboratory or research purposes; engineered antibodies derived from mini-protein toxins for use in the manufacture of pharmaceuticals and drugs

Scientific and technological services, namely scientific research, analysis and testing in the fields of pharmaceuticals, biochemicals, polypeptides, antibodies, ion channel modulating or G-protein-coupled receptor modulating antibodies and antibodies derived from mini-protein toxins; drug discovery and drug development services; conducting or providing research and development services for others in the field of antibodies; scientific and medical research laboratory services relating to the production of antibodies, ion channel modulating or G-protein-coupled receptor modulating antibodies or antibodies derived from mini-protein toxins; antibody engineering; scientific research services relating to the discovery, preclinical and clinical development of therapeutic products; information, advisory and consultancy services in relation to all of the aforesaid

Medical services; medical testing, analysis and diagnostic services in the field of antibodies; medical services connected with the treatment of diseases through the use of antibodies, ion channel blocking antibodies or antibodies derived from mini-protein toxins, or pharmaceuticals, drugs and pharmaceutical preparations derived from the aforesaid; information, advisory and consultancy services in relation to all of the aforesaid

Filing History

NOTICE OF REGISTRATION CONFIRMATION EMAILED
Apr 21, 2026 NRCC
REGISTERED-PRINCIPAL REGISTER
Apr 21, 2026 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Mar 3, 2026 NPUB
PUBLISHED FOR OPPOSITION
Mar 3, 2026 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Feb 25, 2026 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Feb 7, 2026 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Feb 5, 2026 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Feb 5, 2026 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Feb 5, 2026 TROA
REFUSAL PROCESSED BY IB
Jan 1, 2026 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Dec 18, 2025 RFCS
REFUSAL PROCESSED BY MPU
Dec 18, 2025 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Nov 12, 2025 RFCR
NON-FINAL ACTION WRITTEN
Nov 11, 2025 CNRT
ASSIGNED TO EXAMINER
Nov 10, 2025 DOCK
APPLICATION FILING RECEIPT MAILED
Nov 2, 2025 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Nov 2, 2025 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Oct 30, 2025 REPR